Category Archives: – Biotech

Ibrance (palbociclib) to treat advanced breast cancer

Posted on November 1, 2016 by admin

November 28, 2016- Interviewed by Steven E. Greer, MD We interviewed Richard Finn,

Posted in - Biotech, - NEJM, - Pharma, Oncology, UCLA | Leave a comment

The Biggest stories of 2015

Posted on October 20, 2016 by admin

December 31, 2015- by Steven E. Nike Roshe Run Femme Greer, MD 2015 was the year of ISIS. The radical jihadist group started the year with an attack in France,

Posted in - Biotech, - Generics, - Medical Devices, - Opinion, - Pharma, - Policy, - Reviews, books, devices, - The Weekly Summary | Leave a comment

Preventing HIV infection

Posted on February 21, 2016 by admin

July 28, 2014- Interviewed by Steven E. Greer, MD Rajesh Tim Gandhi, MD of the Massachusetts General Hospital discusses the NEJM review paper he co-wrote

Posted in - Biotech, - NEJM, - Pharma, General surgery, Harvard, Infectious disease, Primary care medicine | Leave a comment

The telomerase inhibitor Imetelstat developed by Geron

Posted on February 5, 2016 by admin

September 9, 2015-

Posted in - Biotech, - NEJM, Oncology | Leave a comment

Are the new PCSK9 cholesterol lowering drugs worth the high cost?

Posted on December 7, 2015 by admin

December 16, 2015- Interviewed by Steven E. Greer, MD

Posted in - Biotech, - NEJM, - Opinion, - Pharma, - Policy, Cardiology, CMS, FDA | Leave a comment

Martin Shkreli, CEO of Turing Pharmaceuticals, could be the Bernie Madoff of the drug industry

Posted on September 25, 2015 by admin

September 22, 2015- by Steven E. Greer, MD Making national news today was Martin Shkreli, the baby-faced, greasy-haired, disheveled-looking

Posted in - Biotech, - Pharma, Congress, FDA | Leave a comment

Actavis 1000% drug price hike: a case for healthcare reform

Posted on September 22, 2015 by admin

Update September 21, 2015- The Healthcare Channel was the first to report in 2009 on the business strategy of acquiring cheap generic drugs, cornering the market, then raising

Posted in - Biotech, - Generics, - Opinion, - Policy, CMS, Congress, FDA, Infectious disease | Leave a comment

The PCSK9 LDL drugs do not cut heart risk in half

Posted on March 18, 2015 by admin

March 18, 2015- Op-Ed by Steven E. Greer, MD The American College of Cardiology (ACC) meeting is underway, and the main Late Breaking data

Posted in - Biotech, - Opinion, Cardiac surgery, Cardiology, Primary care medicine | Leave a comment

New therapies for hepatitis C

Posted on November 6, 2013 by admin

November 6, 2013- Interviewed by Steven E. Greer, MD In Part 1, Sammy Saab, MD, MPH, liver disease and GI doctor from UCLA, discusses the standard of care

Posted in - Biotech, - Pharma, Gastroenterology and liver, Infectious disease, UCLA | Leave a comment

Super rapid acting insulin and inhaled insulin

Posted on September 9, 2013 by admin

September 9, 2013- Interviewed by Steven E. Greer, MD Jay Skyler, MD, PhD, Deputy Director of the Diabetes Research Institute at The University

Posted in - Biotech, - Pharma, Diabetes and endocrinology, Univ Miami | Leave a comment

anti-PD1 and anti-PD-L1 drugs treating NSCLC

Posted on March 26, 2013 by admin

March 26, 2013 Interviewed By Steven E. Greer, MD

Posted in - Biotech, - Pharma, Oncology, UCLA | Leave a comment

The Damon Runyon Cancer Research Foundation panel

Posted on March 8, 2013 by admin

March 8, 2013  By Steven E. Greer, MD We interviewed three of the oncologists and industry executives who spoke at the Damon Runyon

Posted in - Biotech, - Pharma, Harvard, Oncology | Leave a comment

Paul Richardson, MD: Three-drug regimen for multiple myeloma

Posted on December 15, 2010 by admin

December 15, 2015 Dr. Paul Richardson of Harvard’s Dana-Farber Cancer Institute reviews the recent Lancet article

Posted in - Biotech, - Pharma, Harvard, Oncology | Leave a comment

Paul Richardson, MD: Current Therapies for Multiple Myeloma

Posted on December 15, 2010 by admin

December 15, 2015- Interviewed by Steven Greer, MD Dr. Paul Richardson, Clinical Director of the Multiple Myeloma Center at Harvard’s Dana-Farber

Posted in - Biotech, - Pharma, Harvard, Oncology | Leave a comment

Steven Cummings, MD: The denosumab FREEDOM trial

Posted on August 11, 2009 by admin

August 11, 2009- Dr. Steven Cummings, director of the San Francisco Coordinating Center and faculty of UCSF, and

Posted in - Biotech, - NEJM, - Pharma, Diabetes and endocrinology, Obstetrics and Gynecology, Orthopedic surgery, Primary care medicine, Radiology, Spine surgery, Sports medicine, UC San Francisco | Leave a comment

Sundeep Khosla, MD discusses Amgen’s Denosumab

Posted on August 11, 2009 by admin

August 11, 2009- Sundeep Khosla of the Mayo Clinic who authored the NEJM editorial on Amgen’s denosumab

Posted in - Biotech, - Pharma, Mayo Clinic | Leave a comment